IDEAYA Biosciences (IDYA) AI Stock Analysis

• Market Cap: $1.58B
• Dividend Yield: N/A
• Average Volume (3M): 958.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: -70.07%
• EPS Growth: -67.97%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 66
• Industry: Biotechnology
• EPS (TTM): -3.30
• Shares Outstanding: 87,537,390
• 10 Day Avg. Volume: 958,278
• 30 Day Avg. Volume: 958,736
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 229.97
• Price to Cash Flow (P/CF): -3.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $53.17
• Price Target Upside: 195.22% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

IDEAYA Biosciences is currently facing financial difficulties with declining revenues and persistent losses, reflected in its financial performance score. The technical indicators show a bearish trend, with the stock being oversold. Its valuation score is low due to negative earnings and lack of dividends, pointing to high risk typical for early-stage biotech firms. While the recent CFO appointment is positive, it's not included in the score calculation due to redundancy. Overall, the stock presents significant risks, but there may be potential for improvement if strategic financial and operational adjustments are made.

Positive Factors

Clinical Pipeline Progress

DLL3 ADC IDE849 clinical update showed a 73% partial response rate in pre-treated SCLC patients, with no adverse events leading to discontinuation.

Financial Stability

IDYA reported cash and cash equivalents at $1.1 billion, which they expect will provide cash runway into 2028.

Strategic Partnerships

The company announced an additional clinical study collaboration and supply agreement with GILD to evaluate the combination of IDE397 with Trodelvy in MTAP-del NSCLC, expanding their ongoing collaboration efforts.

Negative Factors

Future Financial Planning

The most significant change is the addition of $250mn equity raises in 2026, 2027 and 2028 due to an expected increase in cash outflow as the early pipeline advances.

Regulatory Challenges

The company's management noted that the timing for a conference readout on mUM data will be challenging.

Strategic Collaboration Changes

IDYA & AMGN winding down their MTAP collaboration via mutual agreement; clearing event & unsurprising, given IDYA's new internal PRMT5 inhibitor, and mgmt messaging.

IDEAYA Biosciences Business Overview & Revenue Model

Company Description

IDEAYA Biosciences, Inc. (IDYA) is a biotechnology company dedicated to the discovery and development of precision medicine therapies targeting cancer and other genetically defined diseases. The company operates in the field of synthetic lethality, a novel approach to cancer treatment that exploits genetic vulnerabilities in cancer cells. IDEAYA's core products include a pipeline of small molecule therapeutics focused on the areas of synthetic lethality and immuno-oncology.

How the Company Makes Money

IDEAYA Biosciences generates revenue primarily through collaborative research and licensing agreements with pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties from future product sales. Significant collaborations, such as with GlaxoSmithKline (GSK), contribute to its earnings by providing funding for research and development activities. Additionally, IDEAYA may earn revenue from government grants and other funding sources to support its clinical and preclinical programs.

IDEAYA Biosciences Financial Statement Overview

Summary

IDEAYA Biosciences faces significant financial challenges with declining revenues and consistent net losses. The company maintains a strong equity position, suggesting stability, but profitability and cash flow constraints pose risks. Strategic improvements are necessary for future growth.

Income Statement

The company has seen a significant decline in revenue over the past year, with a negative growth rate of 70%. Gross profit margin remains at 100% due to no cost of goods sold reported. However, high negative net profit, EBIT, and EBITDA margins reflect operational challenges and lack of profitability.

Balance Sheet

IDEAYA Biosciences maintains a strong equity base, with an equity ratio of 94%. The debt-to-equity ratio is low, indicating minimal leverage, but return on equity is negative due to net losses, highlighting profitability challenges.

Cash Flow

Operating cash flow and free cash flow are both negative, indicating cash burn from operations. However, the company has managed substantial financing activities, improving cash reserves significantly, albeit not enough to cover the free cash flow deficit.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
7.00M	23.39M	50.93M	27.94M	19.54M
	Gross Profit
7.00M	19.38M	48.83M	26.22M	-20.16M
	EBIT
-326.98M	-134.43M	-62.50M	-50.27M	-35.34M
	EBITDA
-326.98M	-130.42M	-60.40M	-48.54M	-33.96M
	Net Income Common Stockholders
-274.48M	-112.96M	-54.81M	-47.53M	-32.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
676.32M	525.11M	373.15M	368.06M	283.58M
	Total Assets
1.12B	649.32M	387.97M	381.35M	298.27M
	Total Debt
19.17M	2.87M	3.48M	5.18M	6.72M
	Net Debt
-65.21M	-154.15M	-65.15M	-86.86M	-65.31M
	Total Liabilities
64.94M	28.23M	387.97M	381.35M	298.27M
	Stockholders Equity
1.06B	621.09M	349.45M	301.51M	198.27M
Cash Flow		Free Cash Flow
-251.44M	-117.59M	-90.62M	-58.42M	54.97M
	Operating Cash Flow
-247.58M	-115.22M	-87.17M	-55.78M	55.46M
	Investing Cash Flow
-502.56M	-158.46M	-33.40M	-69.67M	-146.24M
	Financing Cash Flow
677.55M	362.72M	97.17M	145.45M	128.75M

IDEAYA Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 18.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Negative. The current price of 18.01 is below the 20-day moving average (MA) of 18.73, below the 50-day MA of 21.07, and below the 200-day MA of 30.11, indicating a bearish trend. The MACD of -0.91 indicates Negative momentum. The RSI at 33.97 is Neutral, neither overbought nor oversold. The STOCH value of 22.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IDYA.

IDEAYA Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZLAB	59 Neutral	$3.88B	―	-31.41%	―	49.59%	24.92%
BEAM	50 Neutral	$2.32B	―	-43.94%	―	-83.18%	-144.95%
Sector *	49 Neutral	$6.88B	0.82	-52.97%	2.48%	20.92%	1.17%
IDYA	45 Neutral	$1.58B	―	-32.67%	―	-70.07%	-67.97%
KURA	45 Neutral	$574.98M	―	-42.91%	―	―	2.90%
FATE	42 Neutral	$103.45M	―	-54.21%	―	-78.55%	-0.92%
REPL	40 Neutral	$823.29M	―	-50.50%	―	―	4.28%

IDEAYA Biosciences Corporate Events

IDEAYA Biosciences Appoints New Chief Financial Officer

On February 10, 2025, IDEAYA Biosciences, a company in the biotechnology sector, announced the appointment of Joshua Bleharski, Ph.D. as its new Chief Financial Officer, effective early May 2025. Dr. Bleharski brings extensive experience from J.P. Morgan, where he served as Managing Director and Global Co-Head of Biopharma, advising on capital markets and corporate strategies. This appointment is expected to strengthen IDEAYA’s leadership team, potentially enhancing its market strategies and investor relations in the biopharma industry.